At the time of writing, Rallybio Corp [RLYB] stock is trading at $0.5, up 1.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The RLYB shares have lost -8.08% over the last week, with a monthly amount glided 19.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rallybio Corp [NASDAQ: RLYB] stock has seen the most recent analyst activity on April 09, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, JP Morgan downgraded its rating to Neutral on May 15, 2024. On February 07, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $1.50 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $18 on April 17, 2023. Wedbush initiated its recommendation with a Outperform and recommended $17 as its price target on April 10, 2023. JP Morgan started tracking with a Overweight rating for this stock on December 09, 2022, and assigned it a price target of $21. In a note dated February 22, 2022, JMP Securities initiated an Mkt Outperform rating and provided a target price of $32 on this stock.
For the past year, the stock price of Rallybio Corp fluctuated between $0.22 and $1.25. Rallybio Corp [NASDAQ: RLYB] shares were valued at $0.5 at the most recent close of the market.
Analyzing the RLYB fundamentals
According to Rallybio Corp [NASDAQ:RLYB], the company’s sales were 0.76M for trailing twelve months, which represents an -29.10% plunge. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -57.03%, Pretax Profit Margin comes in at -54.73%, and Net Profit Margin reading is -54.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.82, Equity is -0.72 and Total Capital is -0.94. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4321 points at the first support level, and at 0.3606 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5431, and for the 2nd resistance point, it is at 0.5826.
Ratios To Look Out For
It is important to note that Rallybio Corp [NASDAQ:RLYB] has a current ratio of 9.98. On the other hand, the Quick Ratio is 9.98, and the Cash Ratio is 1.87. Considering the valuation of this stock, the price to sales ratio is 27.70, the price to book ratio is 0.46.
